Description: Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. It also provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. In addition, the company offers patient recruitment, investment management, medical registration, pharmaceuticals and regulations consulting, drug safety, bioequivalence, and third-party training services, as well as chemistry, management, and controls services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
Home Page: www.tigermedgrp.com
Shengda Science Park, Building A
Hangzhou,
310051
China
Phone:
86 571 2888 7227
Officers
Name | Title |
---|---|
Dr. Xiaoping Ye D.Phil, EMBA, M.D., Ph.D. | Co-Founder & Chairman |
Dr. Xiaochun Cao M.D. | Co-Founder, GM & Executive Director |
Mr. Hao Wu | President & Executive Director |
Ms. Chengcheng Yang | Chief Financial Officer |
Mr. Zengyu Wen | Executive VP, COO & Executive Director |
Ms. Xiao Ri Li | Secretary |
Dr. Tianrong Ji M.D., Ph.D. | Chief Investment Officer |
Mr. Guoyun Yu | Head of Accounting Department |
Mr. Jiansong Yang Ph.D. | Senior VP & Chief Scientific Officer |
Mr. Alan Liu | Chief Compliance Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 17.6678 |
---|---|
Trailing PE: | 28.7143 |
Price-to-Book MRQ: | 1.2687 |
Price-to-Sales TTM: | 0.9767 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 9701 |